As it follows from abovementioned, Enterosgel, as well as other enterosorbents, especially carbon ones, possesses extremely wide spectrum of useful clinical applications.
The magnitude of this list has certain explanations. Firstly, Enterosgel, as all other enterosorbents, is not a pharmacologic preparation in a classical meaning of word, but is related to a category of biomaterials, like, for example, membrane for plasmapheresis that is also used by numerous different indications. Secondly, there is a number of stereotype responses of organism on Enterosgel use that are surprisingly constantly being repeated in experiment and in clinic at various pathological states. To these reactions are related normalization of intestinal microbiocenosis, suppression of lipid peroxidation processes and activation of antioxidant defense, improved indexes of lipidogramme, decreased plasma concentration of molecules with medium molecular weight or their separate fractions, decreased plasma content of CIC and proinflammatory cytokines, and also positive immunomodification by many parameters of cellular and humoral immunity.
In the studies of Т.А. Ageeva et al. (2001) who used the scheme “cyclophosphane-vincristin-prednizolone” for therapy of transplanted lymphosarcoma, it has been registered that administration of Enterosgel to animals decreased an expression of damage of parenchymatosis liver cells and decreased concentration of «medium molecules» in blood serum to 433±0.043 rel.u. versus 0.704±0.037 rel.u. in control without alteration of chemotherapeutic results.
By the opinion of some researchers (О.P. Kaban et al., 1997, 2001; L.М. Gunina et al., 1997), Enterosgel is a useful mean for application in oncosurgery allowing, in particular, to decrease the number of postsurgical complications and relieve the course of postsurgical period in patients with mechanical jaundice, improve indexes of enteric microbiocenosis, decrease concentration of «medium molecules» and decrease intensity of local proteolysis.
In the study of N.А. Gorchakova et al. (2005) Enterogel has been used for treatment of fulminant hepatitis in rats caused by administration of tetrachloromethan. It has been noted that enterosorption hampered lipid peroxidation in liver tissue of experimental animals, elevates activity of enzymes of antioxidant pool, and decreases activity of serum transaminases, what in turn evidences on better preservation of hepatocyte membranes. О.R. Greketal. (2000) who have used multiple administrations of CCl4 in combination with drinking of 5% ethanol for modeling of chronic hepatitis in rats, have demonstrated stable positive effect of Enterosgel administration toward activity of serum transaminases and alkaline phosphatase, as well as the speed of hepatic metabolim of probiotics.
In the work of L.G. Nikolaeva (1993) Enterosgel, along with carbon enterosorbent КАU and lignin enterosorbent Polyphepane, has demonstrated an ability to accelerate the regression of symptoms of acute intestinal infection, decrease the expression of endogenous intoxication, and reduce by 2-3 days the period of seeding of enteric pathogens in patients with Flexner dysenteriae and salmonellosis. In Table 4, impressing data on the influence of Enterosgel administration (1-1.5 g/kg body weight per day) on clinical course of rotaviral infection (intestinal influenza) in 50 newborns, are presented.
In experiments on rats with the model of streptozotocine diabetes, it has been shown a normalizing influence of Enterosgel preparation on the indexes of lipid profile, parameters of prooxidant-antioxidant homeostasis in liver tissue, and its histological structure (V.V. Chernishova et al, 2009). Decrease of concentrations of glycosylated hemoglobin, total cholesterol, triglycerides, lipoproteins of low and high density, urea and lipid hydroperoxides along with simultaneous decrease of concentration of reduced glutathione, catalase, superoxidedismutase, cytochromoxidase, and succinatedehydrogenase activity were found significant compared to control group.